Skip to content

Clinical trials

Enrolling by invitation Overweight trials with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Overweight Phase: Not applicable Status: Enrolling by invitation Clear all

26 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20201
20221
20244
202511
20269

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Enrolling by invitation26

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Centro Universitario de Tlajomulco, Universidad de Guadalajara2
Asma Yahya1
Bioagile Therapeutics Pvt. Ltd.1
Charles University, Czech Republic1
Erasmus Medical Center1
Federico II University1
Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental1
Guy's and St Thomas' NHS Foundation Trust1
Hospital Infantil de Mexico Federico Gomez1
Jaseng Medical Foundation1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Overweight26
Obesity23
Diabetes Mellitus, Type 23
Dyslipidemias2
Hypertension2
Noncommunicable Diseases2
Body Weight Changes1
Cardiovascular Diseases1
Feeding and Eating Disorders1
Glucose Intolerance1

Trials

Showing 1 to 25 of 26. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

  • PLAY2CONTROL Study NCT07556679Completion date change2027-10-31 to 2028-06-30October 18, 2026
  • PLAY2CONTROL Study NCT07556679Status changeNot yet recruiting to Enrolling by invitationOctober 18, 2026

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.